As US cash dries up South Africa's fight to stop Aids gets harder

A US executive order freezing aid commitments threatens an estimated $400m/year in PEPFAR funding to South Africa; the government supplied $46m (about 11.5% of the loss) and the US provided a $115m bridge through end-March. The cuts have reduced testing and prevention services (40% of Desmond Tutu Foundation funding, ~ $8m, came from the US), risk increasing infections (180,000 new HIV cases last year), and imperil research capacity, while the Global Fund has secured 900,000 doses of lenacapavir (enough for 450,000 people) but larger-scale funding is needed to avert a rise in new infections and sustain programs.

Analysis

Market structure: Cuts to US bilateral HIV funding reallocate demand from NGO- and donor-driven service delivery toward pharmaceutical product demand (long‑acting PrEP) and government procurement. Winners: large pharma/compound owners with long‑acting injectable/IP (e.g., GSK/ViiV exposure via GSK; consider selective exposure to PFE if partnered) that can sell higher‑margin, long‑term prophylactics. Losers: South African frontline service providers, local diagnostics volumes, and SA public health budgets—equities and local suppliers face revenue declines of 10–30% in affected programs within 6–12 months.

Risk assessment: Tail risks include a South African sovereign rating downgrade or cashflow squeeze prompting >10% ZAR depreciation and 100–200bp rise in 5‑yr CDS within 3–12 months; operationally, disruption to testing/data could cause a delayed surge in new infections that pressures future procurement. Near term (0–3 months) expect service gaps and lower diagnostic sales; medium term (3–12 months) procurement needs for Lenacapavir/CAB‑LA may surge if governments step in; long term (12–36 months) sustained pharma revenue depends on rollout funding and adherence data.

Trade implications: Direct plays include long pharma exposure to owners of CAB‑LA/lenacapavir (GSK and selectively PFE/GILD) and defensive shorts/put protection on EZA (MSCI South Africa) and ZAR. Use options: buy 6–12 month call spreads on GSK (to cap premium) and buy put spreads on EZA or USDZAR calls to express macro stress. Pair trade: long GSK (2–3% NAV) vs short EZA (2% NAV) to isolate product uptake vs SA macro deterioration over 6–12 months.

Contrarian angles: Consensus assumes permanent US retrenchment; risk of partial restoration or multilateral funding (Global Fund, EU, private donors) within 6–12 months is underpriced, which would re-rate SA equities and reduce ZAR stress. Also, if mobile‑clinic activity rebounds, diagnostics makers (ABT, BDX) could see recovery—so avoid knee‑jerk liquidation of global diagnostics names. History: donor shifts in 2008 led to short spikes in local assets then rehypothecation of funding within 6–18 months; similar mean‑reversion is plausible here.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (ticker: GSK) ADR with a 12‑24 month horizon to capture ViiV/CAB‑LA and long‑acting PrEP revenues; buy a 12‑month 1:2 call spread (debit) sized to a 15–25% upside scenario, take profits at +15% or if WHO/Global Fund announces a large procurement within 6 months.
• Initiate a 1.5–2% short/hedge on South African risk via buying 6–12 month put spreads on EZA (iShares MSCI South Africa ETF) targeting 10–15% downside, or short EZA outright if conviction is high; tighten or close if ZAR stabilizes within 5% of current levels or if national budget (expected within 30–90 days) includes ≥$300m in new HIV funding.
• Buy USDZAR call spreads (3–9 month tenor) sized for a 5–8% ZAR depreciation as a macro hedge; unwind on ZAR move weaker than +8% or if sovereign CDS tightens by >50bp from current levels.
• Pair trade: long GSK (2% NAV) and short EZA (2% NAV) to isolate product uptake from country risk; rebalance after 6 months or upon confirmation of Global Fund/other donor filling >50% of US funding gap.
• Avoid/add protection on diagnostics exposure (ABT, BDX) — do not exit entirely; if testing volumes fall >15% quarter‑on‑quarter, buy 6‑month protective puts (5–10% OTM) sized at 1% NAV to guard against downside while monitoring donor funding flow over next 90 days.